EXUMA Biotech, Corp. announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center of Excellence in Immunology of the National Cancer Institute from September 15 - 16, 2022.
| WEST PALM BEACH, Fla., Sept. 16, 2022 /PRNewswire/ -- Exuma Biotechnology, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies for solid and hematological tumors, announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center of Excellence in Immunology of the National Cancer Institute from September 15 - 16, 2022. Additionally, EXUMA will participate in the 7th Annual CAR-TCR Summit organized by Hanson Wade from September 19-22, 2022, in Boston.
“We are encouraged by the progress of EXUMA’s novel cell and gene therapy platforms, which have the potential to address current challenges with cellular immunotherapies and provide for the next generation of CAR and TCR-based therapies. EXUMA is using advanced lentivectors designed to generate novel cellular therapeutics to treat cancer patients without the need for preparative, lymphodepleting chemotherapy. Our goal is to transform cellular immunotherapy by improving efficacy and safety while also reducing its time, cost, and complexity in order to bring these medicines broadly to patients with significant, unmet medical needs,” said Sid Kerkar, M.D., VP, R&D, Oncology. 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology Participation: Virtual poster presentation with video recording 7th Annual CAR-TCR Summit, Engineering a Disease-Free World Date: September 20-22, 2022 Date: Tuesday, September 20, 2022 Date: Tuesday, September 20, 2022 About EXUMA Biotech EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cell and gene platform immunotherapies for the treatment of solid and hematological tumors. The company is leveraging a global R&D footprint to advance product candidates designed to have reduced cost and complexity with increased safety, efficacy, and scalability compared to existing cell therapies. For more information, visit exumabio.com and connect with us on LinkedIn and Twitter (@ExumaBiotech). Contact
SOURCE EXUMA Biotech Corp. |
View original content to download multimedia:
